Dr. Lim-Seiwert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Summary
- Dr. Tanguy Seiwert is an oncologist in Baltimore, MD. He received his medical degree from Johannes Gutenberg University of Mainz Faculty of Medicine and has been in practice 18 years. He specializes in head & neck cancer and thoracic cancer.
Education & Training
Johannes Gutenberg University of Mainz Faculty of MedicineClass of 1999
Certifications & Licensure
MD State Medical License 2019 - 2026
IL State Medical License 2003 - 2020- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Start of enrollment: 2010 Nov 01
- A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
- Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
- Join now to see all
Publications & Presentations
PubMed
- Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab.Arun Khattri, Nizamuddin Sheikh, Nikhil Agrawal, Sandeep Kaushik, Sara Kochanny
Cancer Gene Therapy. 2024-10-01 - Lower survival for surgical treatment of HPV-related oropharynx cancer at community cancer centers.Danielle R Trakimas, Wojciech K Mydlarz, Leila J Mady, Christine G Gourin, Wayne Koch
Journal of the National Cancer Institute. 2024-09-09 - 1 citationsImmune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.Chester J Kao, Soren Charmsaz, Stephanie L Alden, Madelena Brancati, Howard L Li
The Journal of Clinical Investigation. 2024-08-29
Press Mentions
The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 26th, 2018
Reduced RT Feasible in Chemo-Sensitive HPV-Associated Head and Neck CancerFebruary 19th, 2018
Lower-Dose Radiation Therapy Effective and Safe for HPV-Related Head and Neck Cancer After Induction Chemotherapy, Trial FindsFebruary 13th, 2018- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
